ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2007
Vigabatrin.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Vigabatrin versus carbamazepine monotherapy for epilepsy.The Cochrane database of systematic reviews · 2015Pooled it
- Vigabatrin-related MRI changes and tapering strategy in hemispherotomy for infantile spasms: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- The role of antioxidant and anti-inflammatory mechanisms in the protective effects of vigabatrin against ovarian ischemia-reperfusion injury in a rat model.Journal of ovarian research · 2025Article
- Anti-seizure Medication Induced Cognitive Impairment in Children with Epilepsy: A Narrative Review.Iranian journal of child neurology · 2025Review
- Article
- Design, Synthesis, and Mechanistic Studies of (ACS chemical biology · 2024Article
- A pyridinium-based strategy for lysine-selective protein modification and chemoproteomic profiling in live cells.Chemical science · 2024Article
- Early Treatment with Vigabatrin Does Not Decrease Focal Seizures or Improve Cognition in Tuberous Sclerosis Complex: The PREVeNT Trial.Annals of neurology · 2023Article
- Consensus of the Brazilian Headache Society (SBCe) for the Prophylactic Treatment of Episodic Migraine: part I.Arquivos de neuro-psiquiatria · 2022Article
- The Ameliorative Effect of Empagliflozin in Vigabatrin-Induced Cerebellar/Neurobehavioral Deficits: Targeting mTOR/AMPK/SIRT-1 Signaling Pathways.Molecules (Basel, Switzerland) · 2022Article
- Remarkable and Unexpected Mechanism for (Journal of the American Chemical Society · 2021Article
- Changes in the ERG d-wave with vigabatrin treatment in a pediatric cohort.Documenta ophthalmologica. Advances in ophthalmology · 2014Article
- Clinical trial of vigabatrin as adjunctive therapy in children with refractory epilepsy.Iranian journal of pediatrics · 2013Article
- Management of CNS-related Disease Manifestations in Patients With Tuberous Sclerosis Complex.Current treatment options in neurology · 2013Article
- Non-neuronal, slow GABA signalling in the ventrobasal thalamus targets δ-subunit-containing GABA(A) receptors.The European journal of neuroscience · 2011Article
- Safety and efficacy of vigabatrin for the treatment of infantile spasms.Journal of central nervous system disease · 2011Article
- Reduced grating acuity associated with retinal toxicity in children with infantile spasms on vigabatrin therapy.Investigative ophthalmology & visual science · 2009Article
- Treatment of refractory complex partial seizures: role of vigabatrin.Neuropsychiatric disease and treatment · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Refractory epilepsies such as infantile spasms (IS) and complex partial seizures (CPS) can have a severe negative impact on the neurological integrity and quality of life of affected patients, in addition to drastically increasing their risk of premature mortality. Early identification of potentially effective pharmacotherapy agents is important. Vigabatrin has been shown to be a generally well tolerated and effective antiepileptic drug (AED) in a wide variety of seizure types affecting both children and adults, particularly those with IS and CPS. A bilateral, concentric constriction of the peripheral visual field characterizes the visual field defect (VFD) associated with vigabatrin, well characterized by numerous studies. This peripheral VFD presents in 30-50% of patients with exposure of several years; however, most of these patients are asymptomatic. In well-controlled studies, the earliest onset in patients with CPS is 11 months and at 5 months in infants, with average onsets being more than 5 years and 1 year, respectively. Patients with a peripheral VFD retain an average 65 degrees of lateral vision (normal, 90 degrees). The fact that many patients never develop the vigabatrin-related peripheral VFD, despite long-term exposure at high doses, may support the hypothesis that the injury is an idiosyncratic adverse drug reaction (as opposed to a strict dose- or duration-dependent toxicity). Effective testing methods are available to aid in the early detection and management of the peripheral VFD. This article discusses issues of importance to clinical decision-making in the use of vigabatrin to assist the physician and patient in assessing the benefits of vigabatrin therapy and understanding the potential risks of the VFD and uncontrolled seizures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.